HK Stock Movement | Ascletis Pharma-B (01672) Surges Over 5% Before Noon, ASC30 Shows Significant Competitive Edge, Institutions Highlight High BD Potential

Stock News01-20

Ascletis Pharma-B (01672) surged more than 5% before noon. As of the time of writing, the stock was up 5.12%, trading at HK$13.56, with a turnover of HK$13.2847 million. On the news front, Ascletis Pharma previously announced positive data from its US Phase IIa study of the oral GLP-1 drug ASC30 for the treatment of obesity.

A Citigroup research report stated that this data further demonstrates ASC30's best-in-class potential and strengthens confidence in future collaborations. The report anticipates a positive reaction in the share price, reiterating a "Buy/High Risk" rating with a target price of HK$32.

Oriental Securities noted that ASC30's weight loss data is superior, its safety profile is favorable, and its molecular patent has been granted in the US, indicating significant business development (BD) potential. Furthermore, the subcutaneous injection formulation of ASC30, developed by Ascletis based on its Ultra-Long-Acting Platform (ULAP) for weight loss and maintenance therapy, demonstrates apparent half-lives of 46 days and 75 days, respectively.

This significantly exceeds the half-lives of other ultra-long-acting GLP-1 drugs, while also offering superior safety advantages.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1130092853?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-20 11:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130092853","market":"sg","top_or_hot":-1,"title":"HK Stock Movement | Ascletis Pharma-B (01672) Surges Over 5% Before Noon, ASC30 Shows Significant Competitive Edge, Institutions Highlight High BD Potential","media":"Stock News","content":"<p>Ascletis Pharma-B (01672) surged more than 5% before noon. As of the time of writing, the stock was up 5.12%, trading at HK$13.56, with a turnover of HK$13.2847 million. On the news front, Ascletis Pharma previously announced positive data from its US Phase IIa study of the oral GLP-1 drug ASC30 for the treatment of obesity.</p>\n<p>A Citigroup research report stated that this data further demonstrates ASC30's best-in-class potential and strengthens confidence in future collaborations. The report anticipates a positive reaction in the share price, reiterating a \"Buy/High Risk\" rating with a target price of HK$32.</p>\n<p>Oriental Securities noted that ASC30's weight loss data is superior, its safety profile is favorable, and its molecular patent has been granted in the US, indicating significant business development (BD) potential. Furthermore, the subcutaneous injection formulation of ASC30, developed by Ascletis based on its Ultra-Long-Acting Platform (ULAP) for weight loss and maintenance therapy, demonstrates apparent half-lives of 46 days and 75 days, respectively.</p>\n<p>This significantly exceeds the half-lives of other ultra-long-acting GLP-1 drugs, while also offering superior safety advantages.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | Ascletis Pharma-B (01672) Surges Over 5% Before Noon, ASC30 Shows Significant Competitive Edge, Institutions Highlight High BD Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | Ascletis Pharma-B (01672) Surges Over 5% Before Noon, ASC30 Shows Significant Competitive Edge, Institutions Highlight High BD Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-20 11:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ascletis Pharma-B (01672) surged more than 5% before noon. As of the time of writing, the stock was up 5.12%, trading at HK$13.56, with a turnover of HK$13.2847 million. On the news front, Ascletis Pharma previously announced positive data from its US Phase IIa study of the oral GLP-1 drug ASC30 for the treatment of obesity.</p>\n<p>A Citigroup research report stated that this data further demonstrates ASC30's best-in-class potential and strengthens confidence in future collaborations. The report anticipates a positive reaction in the share price, reiterating a \"Buy/High Risk\" rating with a target price of HK$32.</p>\n<p>Oriental Securities noted that ASC30's weight loss data is superior, its safety profile is favorable, and its molecular patent has been granted in the US, indicating significant business development (BD) potential. Furthermore, the subcutaneous injection formulation of ASC30, developed by Ascletis based on its Ultra-Long-Acting Platform (ULAP) for weight loss and maintenance therapy, demonstrates apparent half-lives of 46 days and 75 days, respectively.</p>\n<p>This significantly exceeds the half-lives of other ultra-long-acting GLP-1 drugs, while also offering superior safety advantages.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"","article_id":"1130092853","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130092853","pubTimestamp":1768881036,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Ascletis Pharma-B (01672) surged more than 5% before noon. As of the time of writing, the stock was up 5.12%, trading at HK$13.56, with a turnover of HK$13.2847 million. On the news front, Ascletis...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1515":"抗疫概念","01672":"歌礼制药-B","01477":"欧康维视生物-B","BK1191":"制药","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"港股动向|歌礼制药-B(01672)午盘前急升超5%ASC30竞争优势显著机构凸显高BD潜力","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1,"01477":1},"content_text":"Ascletis Pharma-B (01672) surged more than 5% before noon. As of the time of writing, the stock was up 5.12%, trading at HK$13.56, with a turnover of HK$13.2847 million. On the news front, Ascletis Pharma previously announced positive data from its US Phase IIa study of the oral GLP-1 drug ASC30 for the treatment of obesity.\nA Citigroup research report stated that this data further demonstrates ASC30's best-in-class potential and strengthens confidence in future collaborations. The report anticipates a positive reaction in the share price, reiterating a \"Buy/High Risk\" rating with a target price of HK$32.\nOriental Securities noted that ASC30's weight loss data is superior, its safety profile is favorable, and its molecular patent has been granted in the US, indicating significant business development (BD) potential. Furthermore, the subcutaneous injection formulation of ASC30, developed by Ascletis based on its Ultra-Long-Acting Platform (ULAP) for weight loss and maintenance therapy, demonstrates apparent half-lives of 46 days and 75 days, respectively.\nThis significantly exceeds the half-lives of other ultra-long-acting GLP-1 drugs, while also offering superior safety advantages.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1130092853","isCrawlerRequest":true}